Acquisition boosts Cambrex's early-stage development capabilities20 Nov 2018
Acquisition adds early-stage API and finished dosage form development & testing services to its global contract development & manufacturing network.
Cambrex has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.
Avista is a portfolio company of Ampersand Capital Partners, a leading healthcare-focused private equity firm. With this acquisition, Cambrex will enter the large and growing market for early-stage small molecule development and testing services. Avista offers a broad suite of scientifically differentiated services ranging from API and drug product development and cGMP manufacturing to stand-alone analytical, microbiology testing and solid state sciences. The acquisition of Avista further strengthens Cambrex’s position as the leading fully integrated small molecule CDMO across the entire drug lifecycle.
“We are excited to announce our acquisition of Avista, which further rounds out our small molecule service offering by adding a full complement of early-stage development capabilities for both API and finished dosage form, as well as comprehensive analytical testing services. The addition of Avista further underscores our commitment to providing the broadest possible range of world-class services to our global customer base,” commented Steve Klosk, President and CEO of Cambrex.
He added: “Like the Halo transaction in September, this acquisition opens up an exciting new segment of the market for Cambrex and brings a large number of new customer relationships to Cambrex. These new relationships will provide cross selling opportunities for Cambrex’s API and finished dosage form services, and will significantly increase the funnel of molecules that may advance to commercial status, where Cambrex has always excelled.”
“This transaction affirms the reputation that our dedicated employee base has established as a trusted early-stage CDMO with a track record of world-class customer service, technical expertise and strong growth,” commented Pat Walsh, CEO of Avista Pharma. “We are very excited to be joining the Cambrex team and believe the growth synergies as a result of this combination will be significant.”
Commenting on the transaction, David Parker, of Ampersand Capital Partners, said: “We are very proud of what has been accomplished by Pat and the entire Avista management team. We believe Avista will continue to generate strong performance under Cambrex’s ownership and we wish Cambrex and the employees of Avista every success. We look forward to following their achievements in the years to come.”
Avista operates four facilities located in Durham, NC, Longmont, CO, Agawam, MA and Edinburgh, Scotland, UK, comprising over 200,000 sq ft of space. All sites have a strong reputation for quality and excellent regulatory track records and contain state of the art assets. Avista has worked on more than 200 small molecules for approximately 180 customers so far in 2018, providing some combination of analytical testing, early-stage process chemistry, formulation development, manufacturing, or solid state chemistry services. Including the microbiological testing business, Avista has over 400 active customers, and is expected to generate approximately $65 million in annual revenue in 2018. Avista’s 330 person workforce will join Cambrex’s 1,700 employees across the US and Europe.
Cambrex will acquire Avista for approximately $252 million in total cash consideration. The acquisition is expected to be funded with a combination of cash on hand and borrowings under Cambrex’s existing revolving credit facility which in conjunction with this transaction, will be increased through the accordion feature. Cambrex has secured committed financing for the proposed increase. Upon completion of the transaction, Cambrex’s net leverage ratio, pro forma for the transaction, is expected to be approximately 2.4 times EBITDA as defined under the Company’s credit agreement. Cambrex expects the transaction to be accretive to adjusted earnings per share in 2019.
Chemspace and LabNetwork collaborate to extend access to chemical databases
14 Feb 2019
Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.Read more
SGS to conduct its first malaria human challenge trial in Belgium
13 Feb 2019
The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.Read more
Post-EU FMD deadline - 'business as usual'?
12 Feb 2019
Partner connectivity will be an immediate and ongoing challenge beyond the deadline and several pharma companies are likely to break agreements with current suppliers through breach of contract clauses.Read more
BASF opens Application Technology Laboratory for personal care in Nigeria
11 Feb 2019
Local competence in application and formulation technology for sub-Saharan African personal care market.Read more
FDA approves first Nanobody-based medicine for adults with aTTP
10 Feb 2019
Cablivi is the first US approval for Sanofi's new rare blood disorders franchise.Read more
Pharmapack Europe 2019 Award Winners
7 Feb 2019
Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.Read more
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
New series of advanced freeze dryers
6 Feb 2019
The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.Read more
Hitachi Chemical to acquire apceth Biopharma
5 Feb 2019
Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.Read more
FDA approves first generic Advair Diskus
4 Feb 2019
Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation